Home›Trial›NCT07486713
NCT07486713Phase 4RECRUITING

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Study Summary

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Conditions
AML (Acute Myeloid Leukemia)GliomaCholangiocarcinomaSolid Tumor Malignancies
Interventions / Drugs
OlutasidenibCYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
View on ClinicalTrials.gov ↗
Sponsor
RIGL
Rigel Pharmaceuticals
Immunology
D40/100
Study Details
Enrollment16 participants
Primary Completion—
Lead SponsorRigel Pharmaceuticals
Data Retrieved2026-04-11 04:25:58.320527+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 16 participants
Sponsor Catalyst Profile

Rigel Pharmaceuticals (RIGL) is the sponsoring company for this trial. BiotechSign currently grades this company D (40/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

RIGL Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.